{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:03:16Z","timestamp":1740106996336,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00520-021-06067-2","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T05:06:48Z","timestamp":1616216808000},"page":"5831-5838","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient-perceived symptomatic benefits of olanzapine treatment for nausea and vomiting in patients with advanced cancer who received palliative care through consultation teams: a multicenter prospective observational study"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0018-3359","authenticated-orcid":false,"given":"Isseki","family":"Maeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Satomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Nishijima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5092-9377","authenticated-orcid":false,"given":"Yoshinobu","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tokoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8081-5979","authenticated-orcid":false,"given":"Keita","family":"Tagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3112-4818","authenticated-orcid":false,"given":"Yoshihisa","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akemi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Iwase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On behalf of the Phase-R N\/V Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Otani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Odagiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroka","family":"Nagaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiko","family":"Mayuzumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Ariyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,20]]},"reference":[{"key":"6067_CR1","doi-asserted-by":"crossref","DOI":"10.1093\/med\/9780199656097.001.0001","volume-title":"Oxford textbook of palliative medicine","author":"NI Cherny","year":"2015","unstructured":"Cherny NI, Fallon M, Kaasa S, Portenoy RK, Currow D (2015) Oxford textbook of palliative medicine, Fifth edn. Oxford University Press, Oxford","edition":"Fifth"},{"issue":"1","key":"6067_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00520-016-3371-3","volume":"25","author":"D Walsh","year":"2017","unstructured":"Walsh D, Davis M, Ripamonti C, Bruera E, Davies A, Molassiotis A (2017) 2016 Updated MASCC\/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer. Support Care Cancer 25(1):333\u2013340. https:\/\/doi.org\/10.1007\/s00520-016-3371-3","journal-title":"Support Care Cancer"},{"issue":"4","key":"6067_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s00520-005-0897-1","volume":"14","author":"J Stephenson","year":"2006","unstructured":"Stephenson J, Davies A (2006) An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer. Support Care Cancer 14(4):348\u2013353. https:\/\/doi.org\/10.1007\/s00520-005-0897-1","journal-title":"Support Care Cancer"},{"issue":"8","key":"6067_CR4","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1007\/s00520-018-4623-1","volume":"27","author":"S Harder","year":"2019","unstructured":"Harder S, Herrstedt J, Isaksen J, Neergaard MA, Frandsen K, Sigaard J, Mondrup L, Jespersen BA, Groenvold M (2019) The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment. Support Care Cancer 27(8):3071\u20133080. https:\/\/doi.org\/10.1007\/s00520-018-4623-1","journal-title":"Support Care Cancer"},{"issue":"1","key":"6067_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1049909112441241","volume":"30","author":"E Prommer","year":"2013","unstructured":"Prommer E (2013) Olanzapine: palliative medicine update. Am J Hosp Palliat Care 30(1):75\u201382. https:\/\/doi.org\/10.1177\/1049909112441241","journal-title":"Am J Hosp Palliat Care"},{"issue":"2","key":"6067_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0893-133x(94)00129-n","volume":"14","author":"FP Bymaster","year":"1996","unstructured":"Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14(2):87\u201396. https:\/\/doi.org\/10.1016\/0893-133x(94)00129-n","journal-title":"Neuropsychopharmacology"},{"issue":"24","key":"6067_CR7","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/jco.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH (2020) Antiemetics: ASCO Guideline Update. J Clin Oncol 38(24):2782\u20132797. https:\/\/doi.org\/10.1200\/jco.20.01296","journal-title":"J Clin Oncol"},{"key":"6067_CR8","unstructured":"National Comprehensive Cancer Network. Antiemesis (Version 2.2020). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed 10th October, 2020"},{"issue":"2","key":"6067_CR9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.critrevonc.2015.02.010","volume":"95","author":"C Fonte","year":"2015","unstructured":"Fonte C, Fatigoni S, Roila F (2015) A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients. Crit Rev Oncol Hematol 95(2):214\u2013221. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.02.010","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"6067_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12904-020-00559-4","volume":"19","author":"G Saudemont","year":"2020","unstructured":"Saudemont G, Prod'Homme C, Da Silva A, Villet S, Reich M, Penel N, Gamblin V (2020) The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature. BMC Palliat Care 19(1):56. https:\/\/doi.org\/10.1186\/s12904-020-00559-4","journal-title":"BMC Palliat Care"},{"issue":"6","key":"6067_CR11","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S0885-3924(02)00391-3","volume":"23","author":"SD Passik","year":"2002","unstructured":"Passik SD, Lundberg J, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E, Cooper M, Dugan W (2002) A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manag 23(6):526\u2013532","journal-title":"J Pain Symptom Manag"},{"issue":"2","key":"6067_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/109662103764978506","volume":"6","author":"WC Jackson","year":"2003","unstructured":"Jackson WC, Tavernier L (2003) Olanzapine for intractable nausea in palliative care patients. J Palliat Med 6(2):251\u2013255. https:\/\/doi.org\/10.1089\/109662103764978506","journal-title":"J Palliat Med"},{"issue":"6","key":"6067_CR13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/s0885-3924(03)00143-x","volume":"25","author":"M Srivastava","year":"2003","unstructured":"Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R (2003) Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manag 25(6):578\u2013582. https:\/\/doi.org\/10.1016\/s0885-3924(03)00143-x","journal-title":"J Pain Symptom Manag"},{"issue":"4","key":"6067_CR14","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jpainsymman.2011.10.023","volume":"44","author":"K Kaneishi","year":"2012","unstructured":"Kaneishi K, Kawabata M, Morita T (2012) Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manag 44(4):604\u2013607. https:\/\/doi.org\/10.1016\/j.jpainsymman.2011.10.023","journal-title":"J Pain Symptom Manag"},{"issue":"1","key":"6067_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1089\/jpm.2015.0224","volume":"19","author":"D MacKintosh","year":"2016","unstructured":"MacKintosh D (2016) Olanzapine in the management of difficult to control nausea and vomiting in a palliative care population: a case series. J Palliat Med 19(1):87\u201390. https:\/\/doi.org\/10.1089\/jpm.2015.0224","journal-title":"J Palliat Med"},{"issue":"7","key":"6067_CR16","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1089\/jpm.2020.0101","volume":"23","author":"K Kaneishi","year":"2020","unstructured":"Kaneishi K, Imai K, Nishimura K, Sakurai N, Kohara H, Ishiki H, Kanai Y, Oyamada S, Yamaguchi T, Morita T, Iwase S (2020) Olanzapine versus metoclopramide for treatment of nausea and vomiting in advanced cancer patients with incomplete malignant bowel obstruction. J Palliat Med 23(7):880\u2013881. https:\/\/doi.org\/10.1089\/jpm.2020.0101","journal-title":"J Palliat Med"},{"issue":"8","key":"6067_CR17","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1007\/s00520-018-4593-3","volume":"27","author":"S Harder","year":"2019","unstructured":"Harder S, Groenvold M, Isaksen J, Sigaard J, Frandsen KB, Neergaard MA, Mondrup L, Herrstedt J (2019) Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study. Support Care Cancer 27(8):2849\u20132856. https:\/\/doi.org\/10.1007\/s00520-018-4593-3","journal-title":"Support Care Cancer"},{"key":"6067_CR18","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2020.1052","volume":"6","author":"RM Navari","year":"2020","unstructured":"Navari RM, Pywell CM, Le-Rademacher JG, White P, Dodge AB, Albany C, Loprinzi CL (2020) Olanzapine for the treatment of advanced cancer-related chronic nausea and\/or vomiting: a randomized pilot trial. JAMA Oncol 6:895\u2013899. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1052","journal-title":"JAMA Oncol"},{"issue":"235","key":"6067_CR19","first-page":"65132","volume":"74","author":"US Food and Drug Administration","year":"2009","unstructured":"US Food and Drug Administration (2009) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist 74(235):65132\u201365133","journal-title":"Fed Regist"},{"issue":"12","key":"6067_CR20","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrclinonc.2017.153","volume":"14","author":"TW LeBlanc","year":"2017","unstructured":"LeBlanc TW, Abernethy AP (2017) Patient-reported outcomes in cancer care - hearing the patient voice at greater volume. Nat Rev Clin Oncol 14(12):763\u2013772. https:\/\/doi.org\/10.1038\/nrclinonc.2017.153","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"6067_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.spinee.2007.01.008","volume":"7","author":"AG Copay","year":"2007","unstructured":"Copay AG, Subach BR, Glassman SD, Polly DW Jr, Schuler TC (2007) Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 7(5):541\u2013546. https:\/\/doi.org\/10.1016\/j.spinee.2007.01.008","journal-title":"Spine J"},{"key":"6067_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.genhosppsych.2020.09.001","volume":"67","author":"I Maeda","year":"2020","unstructured":"Maeda I, Ogawa A, Yoshiuchi K, Akechi T, Morita T, Oyamada S, Yamaguchi T, Imai K, Sakashita A, Matsumoto Y, Uemura K, Nakahara R, Iwase S, Phase RDSG (2020) Safety and effectiveness of antipsychotic medication for delirium in patients with advanced cancer: a large-scale multicenter prospective observational study in real-world palliative care settings. Gen Hosp Psychiatry 67:35\u201341. https:\/\/doi.org\/10.1016\/j.genhosppsych.2020.09.001","journal-title":"Gen Hosp Psychiatry"},{"key":"6067_CR23","doi-asserted-by":"publisher","unstructured":"Shimizu M, Kessoku T, Ishiki H, Matsuura T, Hiratsuka Y, Matsuda Y, Hasegawa T, Imai K, Maeda I, Oyamada S (2019) Naldemedine for opioid-induced constipation in patients receiving palliative care: a real-world registry study (Phase-R OIC Study). J Clin Oncol 37(15):11582\u201311582. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.11582","DOI":"10.1200\/JCO.2019.37.15_suppl.11582"},{"issue":"6","key":"6067_CR24","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1097\/ALN.0b013e3181de0e6d","volume":"112","author":"JT Farrar","year":"2010","unstructured":"Farrar JT, Polomano RC, Berlin JA, Strom BL (2010) A comparison of change in the 0-10 numeric rating scale to a pain relief scale and global medication performance scale in a short-term clinical trial of breakthrough pain intensity. Anesthesiology 112(6):1464\u20131472. https:\/\/doi.org\/10.1097\/ALN.0b013e3181de0e6d","journal-title":"Anesthesiology"},{"issue":"3","key":"6067_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0304-3959(00)00339-0","volume":"88","author":"JT Farrar","year":"2000","unstructured":"Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL (2000) Defining the clinically important difference in pain outcome measures. Pain 88(3):287\u2013294","journal-title":"Pain"},{"key":"6067_CR26","unstructured":"Institute NC (2009) Common Terminology Criteria for Adverse Events v4.0 (CTCAE) https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf. Accessed 10th, October 2020"},{"key":"6067_CR27","unstructured":"Institute NC (2013) NCI Guidelines for investigators: adverse event reporting requirements for DCTD (CTEP AND CIP) AND DCP INDs AND IDEs. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/aeguidelines.pdf. Accessed 10th, October 2020"},{"issue":"1","key":"6067_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1037\/\/0033-2909.112.1.155","volume":"112","author":"J Cohen","year":"1992","unstructured":"Cohen J (1992) A power primer. Psychol Bull 112(1):155\u2013159. https:\/\/doi.org\/10.1037\/\/0033-2909.112.1.155","journal-title":"Psychol Bull"},{"issue":"6","key":"6067_CR29","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1007\/s00520-016-3101-x","volume":"24","author":"K Kaneishi","year":"2016","unstructured":"Kaneishi K, Nishimura K, Sakurai N, Imai K, Matsuo N, Takahashi N, Okamoto K, Suga A, Sano H, Maeda I, Nishina H, Yamaguchi T, Morita T, Iwase S (2016) Use of olanzapine for the relief of nausea and vomiting in patients with advanced cancer: a multicenter survey in Japan. Support Care Cancer 24(6):2393\u20132395. https:\/\/doi.org\/10.1007\/s00520-016-3101-x","journal-title":"Support Care Cancer"},{"issue":"2","key":"6067_CR30","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jpainsymman.2012.07.022","volume":"46","author":"G Bedard","year":"2013","unstructured":"Bedard G, Zeng L, Zhang L, Lauzon N, Holden L, Tsao M, Danjoux C, Barnes E, Sahgal A, Poon M, Chow E (2013) Minimal clinically important differences in the edmonton symptom assessment system in patients with advanced cancer. J Pain Symptom Manag 46(2):192\u2013200. https:\/\/doi.org\/10.1016\/j.jpainsymman.2012.07.022","journal-title":"J Pain Symptom Manag"},{"issue":"10","key":"6067_CR31","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1007\/s11136-016-1308-4","volume":"25","author":"S Raman","year":"2016","unstructured":"Raman S, Ding K, Chow E, Meyer RM, Nabid A, Chabot P, Coulombe G, Ahmed S, Kuk J, Dar AR, Mahmud A, Fairchild A, Wilson CF, Wu JSY, Dennis K, DeAngelis C, Wong RKS, Zhu L, Brundage M (2016) Minimal clinically important differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL modules in patients with bone metastases undergoing palliative radiotherapy. Qual Life Res 25(10):2535\u20132541. https:\/\/doi.org\/10.1007\/s11136-016-1308-4","journal-title":"Qual Life Res"},{"issue":"4","key":"6067_CR32","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1080\/10543400902964118","volume":"19","author":"J Shao","year":"2009","unstructured":"Shao J, Jordan DC, Pritchett YL (2009) Baseline observation carry forward: reasoning, properties, and practical issues. J Biopharm Stat 19(4):672\u2013684","journal-title":"J Biopharm Stat"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06067-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06067-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06067-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T01:28:15Z","timestamp":1671672495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06067-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,20]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["6067"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06067-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2021,3,20]]},"assertion":[{"value":"12 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and the requirements set forth by the Japanese Ethical Guidelines for Epidemiology Research. Study protocol was reviewed and approved by institutional review boards of all participating sites. Opt-out methods were employed and written informed consent was waived according to the Japanese Ethical Guidelines for Epidemiology Research and the guidance of institutional review boards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}